179 related articles for article (PubMed ID: 16650231)
1. Vitiligo-like lesions and diffuse lightening of the skin in a pediatric patient treated with imatinib mesylate: a noninvasive colorimetric assessment.
Brazzelli V; Roveda E; Prestinari F; Barbagallo T; Bellani E; Trevisan V; Rona C; Locatelli F; Zecca M; Borroni G
Pediatr Dermatol; 2006; 23(2):175-8. PubMed ID: 16650231
[TBL] [Abstract][Full Text] [Related]
2. A long-term time course of colorimetric assessment of the effects of imatinib mesylate on skin pigmentation: a study of five patients.
Brazzelli V; Prestinari F; Barbagallo T; Rona C; Orlandi E; Passamonti F; Locatelli F; Zecca M; Villani S; Borroni G
J Eur Acad Dermatol Venereol; 2007 Mar; 21(3):384-7. PubMed ID: 17309464
[TBL] [Abstract][Full Text] [Related]
3. Vitiligo-like lesions in an adult patient treated with Imatinib mesylate.
Cerchione C; Fabbricini R; Pane F; Luciano L
Leuk Res; 2009 Aug; 33(8):e104-5. PubMed ID: 19232719
[No Abstract] [Full Text] [Related]
4. Imatinib mesylate causes hypopigmentation in the skin.
Tsao AS; Kantarjian H; Cortes J; O'Brien S; Talpaz M
Cancer; 2003 Dec; 98(11):2483-7. PubMed ID: 14635084
[TBL] [Abstract][Full Text] [Related]
5. Oral pigmentation in the hard palate associated with imatinib mesylate therapy: a report of three cases.
Mattsson U; Halbritter S; Mörner Serikoff E; Christerson L; Warfvinge G
Oral Surg Oral Med Oral Pathol Oral Radiol Endod; 2011 May; 111(5):e12-6. PubMed ID: 21330162
[TBL] [Abstract][Full Text] [Related]
6. Development of lichen sclerosus et atrophicus while receiving a therapeutic dose of imatinib mesylate for chronic myelogenous leukemia.
Skupsky H; Abuav R; High W; Pass C; Goldenberg G
J Cutan Pathol; 2010 Aug; 37(8):877-80. PubMed ID: 19703239
[TBL] [Abstract][Full Text] [Related]
7. Imatinib mesylate induced skin hypopigmentation.
Talwar V; Doval DC; Bhatia K
J Assoc Physicians India; 2007 Jul; 55():527. PubMed ID: 17907508
[No Abstract] [Full Text] [Related]
8. Pigmentary changes in a patient treated with imatinib.
Balagula Y; Pulitzer MP; Maki RG; Myskowski PL
J Drugs Dermatol; 2011 Sep; 10(9):1062-6. PubMed ID: 22052279
[TBL] [Abstract][Full Text] [Related]
9. Hematological and molecular response evaluation of CML patients on imatinib.
Gupta A; Prasad K
J Assoc Physicians India; 2007 Feb; 55():109-13. PubMed ID: 17571739
[TBL] [Abstract][Full Text] [Related]
10. A comprehensive review of imatinib mesylate (Gleevec) for dermatological diseases.
Scheinfeld N
J Drugs Dermatol; 2006 Feb; 5(2):117-22. PubMed ID: 16485879
[TBL] [Abstract][Full Text] [Related]
11. Hypopigmented macules secondary to imatinib for the treatment of chronic myeloid leukemia: a histopathologic and immunohistochemical study.
Llamas-Velasco M; Fraga J; Kutzner H; Steegmann JL; García-Diez A; Requena L
J Cutan Pathol; 2014 May; 41(5):417-26. PubMed ID: 24467724
[TBL] [Abstract][Full Text] [Related]
12. Acute myeloid leukemia developing during imatinib mesylate therapy for chronic myeloid leukemia in the absence of new cytogenetic abnormalities.
Pawarode A; Sait SN; Nganga A; Coignet LJ; Barcos M; Baer MR
Leuk Res; 2007 Nov; 31(11):1589-92. PubMed ID: 17391756
[TBL] [Abstract][Full Text] [Related]
13. Ocular side effects in chronic myeloid leukemia patients treated with imatinib.
Breccia M; Gentilini F; Cannella L; Latagliata R; Carmosino I; Frustaci A; Alimena G
Leuk Res; 2008 Jul; 32(7):1022-5. PubMed ID: 18061664
[TBL] [Abstract][Full Text] [Related]
14. Heliotrope-like eruption mimicking dermatomyositis in a patient treated with imatinib mesylate for chronic myeloid leukemia.
Kuwano Y; Asahina A; Watanabe R; Fujimoto M; Ihn H; Tamaki K
Int J Dermatol; 2006 Oct; 45(10):1249-51. PubMed ID: 17040457
[No Abstract] [Full Text] [Related]
15. Pityriasis rosea-like eruption during treatment with imatinib mesylate: description of 3 cases.
Brazzelli V; Prestinari F; Roveda E; Barbagallo T; Bellani E; Vassallo C; Orlandi E; Passamonti F; Borroni G
J Am Acad Dermatol; 2005 Nov; 53(5 Suppl 1):S240-3. PubMed ID: 16227099
[TBL] [Abstract][Full Text] [Related]
16. Imatinib mesylate-related fatal acute hepatic failure in a patient with chronic myeloid leukaemia and chronic hepatitis B infection.
Thia TJ; Tan HH; Chuah TH; Chow WC; Lui HF
Singapore Med J; 2008 Mar; 49(3):e86-9. PubMed ID: 18362995
[TBL] [Abstract][Full Text] [Related]
17. Partial fanconi syndrome induced by imatinib therapy: a novel cause of urinary phosphate loss.
François H; Coppo P; Hayman JP; Fouqueray B; Mougenot B; Ronco P
Am J Kidney Dis; 2008 Feb; 51(2):298-301. PubMed ID: 18215707
[TBL] [Abstract][Full Text] [Related]
18. [Imatinib-induced DRESS].
Goldman J; Duval-Modeste AB; Lambert A; Contentin N; Courville P; Musette P; Joly P
Ann Dermatol Venereol; 2008 May; 135(5):393-6. PubMed ID: 18457727
[TBL] [Abstract][Full Text] [Related]
19. Development of hypogammaglobulinemia in patients treated with imatinib for chronic myeloid leukemia or gastrointestinal stromal tumor.
Santachiara R; Maffei R; Martinelli S; Arcari A; Piacentini F; Trabacchi E; Alfieri P; Ferrari A; Leonardi G; Luppi G; Longo G; Vallisa D; Marasca R; Torelli G
Haematologica; 2008 Aug; 93(8):1252-5. PubMed ID: 18519520
[TBL] [Abstract][Full Text] [Related]
20. [Intestinal bleeding during the treatment of chronic myeloid leukemia with imatinib mesylate].
Yokote T; Akioka T; Nakayama S; Oka S; Hara S; Yamano T; Tsuji M; Hanafusa T
Rinsho Ketsueki; 2005 Sep; 46(9):1060-4. PubMed ID: 16440765
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
